Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2017 Archives
Jun 16, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amantadine... More |
May 26, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that its chief executive officer, Arthur Bedrosian, received a top rating in a report by Owler, the world's largest community-based business... More |
May 16, 2017 Lannett Announces Approval For Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL (0.5 mg/mL) Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levocetirizine... More |
May 9, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily paid down the remaining principal balance of $25 million against its existing revolving credit facility. "Since... More |
May 2, 2017 Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 third quarter ended March 31, 2017. "Net sales in our fiscal 2017 third quarter increased compared with the... More |
Apr 28, 2017 Lannett Company, Inc. (NYSE: LCI) today announced its participation at three upcoming investor conferences. These include the: Deutsche Bank 42nd Annual Health Care Conference at 8 a.m. ET, on... More |
Apr 25, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 third quarter on Tuesday, May 2, 2017, after the market closes. Lannett management will... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $25 million payment against its existing revolving credit facility. "This $25 million payment, combined with... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its former chairman and chief executive officer William (Bill) Farber, R. Ph., has passed away from natural causes. Mr. Farber served as the... More |
Lannett Company, Inc. (NYSE: LCI) today announced its participation at four upcoming investor conferences. These include: Deutsche Bank's Pharma One-on-One Day, to be held at the JW Marriott... More |
--Kristin Arnold, Ph.D., Joins as Vice President of Research and Development-- Lannett Company, Inc. (NYSE: LCI) today announced that Kristin A. Arnold, Ph.D., has joined the company as vice president of research and development, effective February 27, 2017. "As head of... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it was notified by U.S. Food and Drug Administration (FDA) late yesterday afternoon that FDA suspended indefinitely the deadline for the... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the extraction of the core software supporting the operations of Kremers Urban Pharmaceuticals, Inc. (KU) from UCB Pharma.... More |
--Net Sales Increased 35% to Approximately $171 Million; Company Continues to Expect Strong Fiscal Year-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 second quarter ended December 31, 2016. The company completed the acquisition of Kremers Urban... More |
Jan 25, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 second quarter on Wednesday, February 1, 2017, after the market closes. Lannett... More |
Jan 23, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $75 million payment against its existing revolving credit facility. "This payment is consistent with our... More |
Jan 3, 2017 --Company May Be Eligible for 180 Days of Generic Drug Marketing Exclusivity-- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval last week from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lopinavir... More |
| 1-25 26-42 |